Omnicell Investor Presentation Deck slide image

Omnicell Investor Presentation Deck

Updated 2023 Guidance Adjusted to include the anticipated effects and expected impact of current macroeconomic headwinds. Bookings¹ Total Revenues Product Revenues Service Revenues Technical Services Revenues Advanced Services Revenues Non-GAAP EBITDA Non-GAAP EPS Q4-2023 Not guided $247-$267 Million $142-$152 Million $105-$115 Million Not guided Not guided $9-$19 Million $0.07-$0.22 TY-2023 $850 Million -$950 Million $1.135-$1.155 Billion $705-$715 Million $430-$440 Million $222-$227 Million $208-$213 Million $123-$133 Million $1.65-$1.80 We do not provide a reconciliation of forward-looking non-GAAP guidance to the comparable GAAP measures as these items are inherently uncertain and difficult to estimate and cannot be predicted without unreasonable effort. 1. We define bookings generally as: (i) the value of non-cancelable contracts for our connected devices, software products, and Advanced Services (although, for those Advanced Services contracts without a minimum commitment, bookings only includes the amount of revenue that has been recognized once the services have been provided); and (ii) for our consumables, the value of orders placed through our Omnicell Storefront online platform or through written or telephonic orders. We typically exclude technical services and other less significant items ancillary to our products and services, such as freight revenue from bookings. 2. Represents estimated cumulative TAM over 10 years as of 5/31/2022 and includes the United States, UK&I, Germany, France, Spain, Kingdom of Saudi Arabia and Australia/New Zealand. © 2023 Omnicell, Inc. Long-Term Value Creation Opportunities Leadership position in the digital transformation of healthcare with $90 Billion+ TAM² Emerging and scaling of Advanced Services offerings Platform adoption, expansion, market share gains, and upgrade cycles supporting growth Strong balance sheet should enable transformation to new business model with expected higher gross margins, EBITDA, and free cash flows 16
View entire presentation